"Beta-l-thymidine"@en . . "1-(2-Deoxy-beta-L-ribofuranosyl)-5-methyluracil"@en . "LDT"@en . "Telbivudin"@en . . "Hepatitis B virus"@en . "investigational"@en . . . "# Matthews SJ: Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther. 2007 Dec;29(12):2635-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18201580 # Amarapurkar DN: Telbivudine: a new treatment for chronic hepatitis B. World J Gastroenterol. 2007 Dec 14;13(46):6150-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18069753 # Dusheiko G, Danta M: Telbivudine for the treatment of chronic hepatitis B. Drugs Today (Barc). 2007 May;43(5):293-304. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17724496 # Keam SJ: Telbivudine. Drugs. 2007;67(13):1917-29. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17722961 # Ruiz-Sancho A, Sheldon J, Soriano V: Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opin Biol Ther. 2007 May;7(5):751-61. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17477811 # Marcellin P, Asselah T, Boyer N: Treatment of chronic hepatitis B. J Viral Hepat. 2005 Jul;12(4):333-45. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15985003 # Han SH: Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2005 Apr;14(4):511-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15882124 # Jones R, Nelson M: Novel anti-hepatitis B agents: A focus on telbivudine. Int J Clin Pract. 2006 Oct;60(10):1295-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16981973"@en . "3424-98-4"@en . . "Approximately 15 hours."@en . "There is no information on intentional overdose of telbivudine, but one subject experienced an unintentional and asymptomatic overdose. Healthy subjects who received telbivudine doses up to 1800 mg/day for 4 days had no increase in or unexpected adverse events. A maximum tolerated dose for telbivudine has not been determined."@en . . . . . . . . . . "Telbivudine 5'\u2013triphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate, thymidine 5'\u2013triphosphate. This leads to the chain termination of DNA synthesis, thereby inhibiting viral replication. Incorporation of telbivudine 5'\u2013triphosphate into viral DNA also causes DNA chain termination, resulting in inhibition of HBV replication. Telbivudine inhibits anticompliment or second-strand DNA."@en . . . . "Telbivudine"@en . . "Epavudine"@en . "* 7.6 +/- 2.9 L/h [Normal renal function (Clcr>80 mL/min)] * 5.0 +/- 1.2 L/h [Mild renal function impairement (Clcr=50-80 mL/min)] * 2.6 +/- 1.2 L/h [Moderate renal function impairement (Clcr=30-49 mL/min)] * 0.7 +/- 0.4 L/h [Severe renal function impairement (Clcr<30 mL/min)]"@en . . . . "Telbivudine is eliminated primarily by urinary excretion of unchanged drug."@en . . . . "approved"@en . . . . . . "Absorbed following oral administration. Telbivudine absorption and exposure were unaffected when a single 600\u2013mg dose was administered with a high\u2013fat (~55 g), high\u2013calorie (~950 kcal) meal."@en . . . . . . . "beta-L-2'-Deoxythymidine"@en . . . . . . . . . . . . "L-thymidine"@en . . . . "In vitro binding of telbivudine to human plasma proteins is low (3.3%)."@en . "L-DT"@en . . "Take without regard to meals."@en . "For the treatment of chronic hepatitis B in adult and adolescent patients \u226516 years of age with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease."@en . "Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects."@en . . . "2'-Deoxy-L-thymidine"@en . "L-deoxythymidine"@en .